STX Stock Overview
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs.
+ 1 more risk
Shield Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.088|
|52 Week High||UK£0.52|
|52 Week Low||UK£0.055|
|1 Month Change||-27.87%|
|3 Month Change||36.96%|
|1 Year Change||-75.56%|
|3 Year Change||-95.15%|
|5 Year Change||-94.41%|
|Change since IPO||-94.40%|
Recent News & Updates
|STX||GB Pharmaceuticals||GB Market|
Return vs Industry: STX underperformed the UK Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: STX underperformed the UK Market which returned -12.6% over the past year.
|STX Average Weekly Movement||14.2%|
|Pharmaceuticals Industry Average Movement||7.1%|
|Market Average Movement||5.6%|
|10% most volatile stocks in GB Market||10.7%|
|10% least volatile stocks in GB Market||2.9%|
Stable Share Price: STX is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: STX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company’s lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Shield Therapeutics Fundamentals Summary
|STX fundamental statistics|
Is STX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|STX income statement (TTM)|
|Cost of Revenue||UK£1.45m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.093|
|Net Profit Margin||-776.64%|
How did STX perform over the long term?See historical performance and comparison
Is STX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for STX?
Other financial metrics that can be useful for relative valuation.
|What is STX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does STX's PS Ratio compare to its peers?
|STX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
EAH ECO Animal Health Group
AGY Allergy Therapeutics
ANCR Animalcare Group
STX Shield Therapeutics
Price-To-Sales vs Peers: STX is good value based on its Price-To-Sales Ratio (7.4x) compared to the peer average (14.2x).
Price to Earnings Ratio vs Industry
How does STX's PE Ratio compare vs other companies in the GB Pharmaceuticals Industry?
Price-To-Sales vs Industry: STX is expensive based on its Price-To-Sales Ratio (7.4x) compared to the European Pharmaceuticals industry average (3.8x)
Price to Sales Ratio vs Fair Ratio
What is STX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||7.4x|
|Fair PS Ratio||111.7x|
Price-To-Sales vs Fair Ratio: STX is good value based on its Price-To-Sales Ratio (7.4x) compared to the estimated Fair Price-To-Sales Ratio (111.7x).
Share Price vs Fair Value
What is the Fair Price of STX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate STX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate STX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Shield Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).
Earnings vs Market: STX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: STX is expected to become profitable in the next 3 years.
Revenue vs Market: STX's revenue (105.2% per year) is forecast to grow faster than the UK market (3.5% per year).
High Growth Revenue: STX's revenue (105.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if STX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Shield Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STX is currently unprofitable.
Growing Profit Margin: STX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: STX is unprofitable, and losses have increased over the past 5 years at a rate of 3.5% per year.
Accelerating Growth: Unable to compare STX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.1%).
Return on Equity
High ROE: STX has a negative Return on Equity (-73.18%), as it is currently unprofitable.
Discover strong past performing companies
How is Shield Therapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: STX's short term assets (£8.4M) exceed its short term liabilities (£3.3M).
Long Term Liabilities: STX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: STX is debt free.
Reducing Debt: STX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: STX has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.3% each year.
Discover healthy companies
What is Shield Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Shield Therapeutics Dividend Yield vs Market|
|Company (Shield Therapeutics)||n/a|
|Market Bottom 25% (GB)||2.1%|
|Market Top 25% (GB)||6.0%|
|Industry Average (Pharmaceuticals)||3.5%|
|Analyst forecast in 3 Years (Shield Therapeutics)||0%|
Notable Dividend: Unable to evaluate STX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if STX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as STX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Greg Madison (54 yo)
Mr. Gregory P. Madison, also known as Greg, was the Chief Executive Officer and President of Keryx Biopharmaceuticals Inc. since 2015 until April 27, 2018. Mr. Madison serves as Chief Executive Officer at...
CEO Compensation Analysis
|Greg Madison's Compensation vs Shield Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||UK£433k||UK£218k|
Compensation vs Market: Greg's total compensation ($USD483.98K) is above average for companies of similar size in the UK market ($USD338.02K).
Compensation vs Earnings: Insufficient data to compare Greg's compensation with company performance.
Experienced Management: STX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: STX's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
|State or Government||922,579||0.4%|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.2%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Shield Therapeutics plc's employee growth, exchange listings and data sources
- Name: Shield Therapeutics plc
- Ticker: STX
- Exchange: AIM
- Founded: 2008
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: UK£22.650m
- Shares outstanding: 257.39m
- Website: https://www.shieldtherapeutics.com
Number of Employees
- Shield Therapeutics plc
- Northern Design Centre
- Baltic Business Quarter
- Tyne and Wear
- NE8 3DF
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|STX||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Feb 2016|
|1JS||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Feb 2016|
|SHIE.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Feb 2016|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/06 00:00|
|End of Day Share Price||2022/10/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.